Vascular calcification revisited: A new perspective for phosphate transport

Current Cardiology Reviews

Volumn 11, Issue 4, 2015, Pages 341-351

  Villa Bellosta, Ricardo ^a  

^a CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

Author keywords

ATP; Calcium; Phosphate; Pyrophosphate; Vascular calcification

Indexed keywords

5' NUCLEOTIDASE; ADENOSINE DIPHOSPHATE; ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; CALCIUM PHOSPHATE; CALCIUM PHOSPHATE DIBASIC; CD39 ANTIGEN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; GAP JUNCTION PROTEIN; HYDROXYAPATITE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 6; PHOSPHATE BINDING AGENT; SODIUM PHOSPHATE COTRANSPORTER;

ANKYLOSIS; ARTHRITIS; ARTICLE; BIOMINERALIZATION; BLOOD VESSEL CALCIFICATION; CALCIFICATION; CHONDROCALCINOSIS; GENETIC DISORDER; HUMAN; NONHUMAN; PHOSPHATE TRANSPORT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 84947922251     PISSN: 1573403X     EISSN: 18756557     Source Type: Journal    
DOI: 10.2174/1573403X11666150805120505     Document Type: Article

References (130)

1. Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res 2011; 109: 697-711.
2. Rutsch F, Nitschke Y, Terkeltaub R. Genetics in arterial calcification: pieces of a puzzle and cogs in a wheel. Circ Res 2011; 109: 578-92.
3. Monckeberg JG. Uber die reine mediaverkalkung der extremitatenarterien und ihr verhalten zur arteriosklerose. Virchows Arch Pathol Anat 1902; 171: 141-67.
4. Rocha-Singh KJ, Zeller T, Jaff MR. Peripheral arterial calcification: Prevalence, mechanism, detection, and clinical implications. Catheter Cardiovasc Interv 2014.
5. Urry DW. Neutral sites for calcium ion binding to elastin and collagen: a charge neutralization theory for calcification and its relationship to atherosclerosis. Proc Natl Acad Sci U S A 1971; 68: 810-14.
6. Giachelli CM. The emerging role of phosphate in vascular calcification. Kidney Int 2009; 75: 890-7.
7. Villa-Bellosta R, Millan A, Sorribas V. Role of calcium-phosphate deposition in vascular smooth muscle cell calcification. Am J Physiol Cell Physiol 2011; 300: C210-220.
8. Villa-Bellosta R, Sorribas V. Phosphonoformic acid prevents vascular smooth muscle cell calcification by inhibiting calciumphosphate deposition. Arterioscler Thromb Vasc Biol 2009; 29: 761-6.
9. Ketteler M, Biggar PH. Use of phosphate binders in chronic kidney disease. Curr Opin Nephrol Hypertens 2013; 22: 413-20.
10. Malberti F. Hyperphosphataemia: treatment options. Drugs 2013; 73: 673-88.
11. Jono S, McKee MD, Murry CE et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000; 87: E10- 17.
12. Li X, Yang HY, Giachelli CM. Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ Res 2006; 98: 905-12.
13. MacGregor J, Robertson WG, Nordin BE. Octocalcium phosphate: the phase governing the solubility equilibrium in apatitic calculi. Br J Urol 1965; 37: 518-24.
14. Schibler D, Russell RG, Fleisch H. Inhibition by pyrophosphate and polyphosphate of aortic calcification induced by vitamin D3 in rats. Clin Sci 1968; 35: 363-72.
15. Schinke T, Karsenty G. Vascular calcification--a passive process in need of inhibitors. Nephrol Dial Transplant 2000; 15: 1272-4.
16. O'Neill WC. Vascular calcification: not so crystal clear. Kidney Int 2007; 71: 282-3.
17. Proudfoot D, Skepper JN, Hegyi L et al. Apoptosis regulates human vascular calcification in vitro: evidence for initiation of vascular calcification by apoptotic bodies. Circ Res 2000; 87: 1055-62.
18. Ewence AE, Bootman M, Roderick HL et al. Calcium phosphate crystals induce cell death in human vascular smooth muscle cells: a potential mechanism in atherosclerotic plaque destabilization. Circ Res 2008; 103: e28-34.
19. Shroff RC, McNair R, Figg N et al. Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation 2008; 118: 1748-57.
20. Steitz SA, Speer MY, Curinga G et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res 2001; 89: 1147-54.
21. Li X, Yang HY, Giachelli CM. BMP-2 promotes phosphate uptake, phenotypic modulation, and calcification of human vascular smooth muscle cells. Atherosclerosis 2008; 199: 271-7.
22. Speer MY, Li X, Hiremath PG, Giachelli CM. Runx2/Cbfa1, but not loss of myocardin, is required for smooth muscle cell lineage reprogramming toward osteochondrogenesis. J Cell Biochem 2010; 110: 935-47.
23. Sage AP, Lu J, Tintut Y, Demer LL. Hyperphosphatemia-induced nanocrystals upregulate the expression of bone morphogenetic protein-2 and osteopontin genes in mouse smooth muscle cells in vitro. Kidney Int 2011; 79: 414-22.
24. Lei Y, Sinha A, Nosoudi N et al. Hydroxyapatite and calcified elastin induce osteoblast-like differentiation in rat aortic smooth muscle cells. Exp Cell Res 2014.
25. Villa-Bellosta R, Sorribas V. Calcium phosphate deposition with normal phosphate concentration. -Role of pyrophosphate. Circ J 2011; 75: 2705-10.
26. Fish RS, Klootwijk E, Tam FW et al. ATP and arterial calcification. Eur J Clin Invest 2013; 43: 405-12.
27. Zimmermann H. Extracellular metabolism of ATP and other nucleotides. Naunyn Schmiedebergs Arch Pharmacol 2000; 362: 299-309.
28. O'Neill WC, Lomashvili KA, Malluche HH et al. Treatment with pyrophosphate inhibits uremic vascular calcification. Kidney Int 2010; 79: 512-7.
29. Riser BL, Barreto FC, Rezg R et al. Daily peritoneal administration of sodium pyrophosphate in a dialysis solution prevents the development of vascular calcification in a mouse model of uraemia. Nephrol Dial Transplant 2011; 26: 3349-57.
30. Villa-Bellosta R, Rivera-Torres J, Osorio FG et al. Defective extracellular pyrophosphate metabolism promotes vascular calcification in a mouse model of Hutchinson-Gilford progeria syndrome that is ameliorated on pyrophosphate treatment. Circulation 2013; 127: 2442-51.
31. Prosdocimo DA, Douglas DC, Romani AM et al. Autocrine ATP release coupled to extracellular pyrophosphate accumulation in vascular smooth muscle cells. Am J Physiol Cell Physiol 2009; 296: C828-839.
32. Villa-Bellosta R, Sorribas V. Prevention of vascular calcification by polyphosphates and nucleotides- role of ATP. Circ J 2013; 77: 2145-51.
33. O'Neill WC. Pyrophosphate, alkaline phosphatase, and vascular calcification. Circ Res 2006; 99: e2.
34. Grases F, Sanchis P, Perello J et al. Effect of crystallization inhibitors on vascular calcifications induced by vitamin D: a pilot study in Sprague-Dawley rats. Circ J 2007; 71: 1152-6.
35. Lomashvili KA, Monier-Faugere MC, Wang X et al. Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure. Kidney Int 2009; 75: 617-25.
36. Warraich S, Bone DB, Quinonez D et al. Loss of equilibrative nucleoside transporter 1 in mice leads to progressive ectopic mineralization of spinal tissues resembling diffuse idiopathic skeletal hyperostosis in humans. J Bone Miner Res 2013; 28: 1135- 49.
37. Sugita A, Kawai S, Hayashibara T et al. Cellular ATP synthesis mediated by type III sodium-dependent phosphate transporter Pit-1 is critical to chondrogenesis. J Biol Chem 2011; 286: 3094-3103.
38. Wang C, Li Y, Shi L et al. Mutations in SLC20A2 link familial idiopathic basal ganglia calcification with phosphate homeostasis. Nat Genet 2012; 44: 254-6.
39. Lohman AW, Billaud M, Isakson BE. Mechanisms of ATP release and signalling in the blood vessel wall. Cardiovasc Res 2012; 95: 269-80.
40. Villa-Bellosta R, Bogaert YE, Levi M, Sorribas V. Characterization of phosphate transport in rat vascular smooth muscle cells: implications for vascular calcification. Arterioscler Thromb Vasc Biol 2007; 27: 1030-36.
41. Johnsson MS, Nancollas GH. The role of brushite and octacalcium phosphate in apatite formation. Crit Rev Oral Biol Med 1992; 3: 61-82.
42. LeGeros RZ. Calcium phosphates in oral biology and medicine. Monogr Oral Sci 1991; 15: 1-201.
43. LeGeros RZ. Formation and transformation of calcium phosphates: relevance to vascular calcification. Z Kardiol 2001; 90 Suppl 3: 116-124.
44. O'Neill WC. The fallacy of the calcium-phosphorus product. Kidney Int 2007; 72: 792-6.
45. Kodaka T, Debari K, Higashi S. Magnesium-containing crystals in human dental calculus. J Electron Microsc (Tokyo) 1988; 37: 73- 80.
46. Scotchford CA, Ali SY. Magnesium whitlockite deposition in articular cartilage: a study of 80 specimens from 70 patients. Ann Rheum Dis 1995; 54: 339-44.
47. Reid JD, Andersen ME. Medial calcification (whitlockite) in the aorta. Atherosclerosis 1993; 101: 213-24.
48. P'Ng C H, Boadle R, Horton M et al. Magnesium whitlockite of the aorta. Pathology 2008; 40: 539-40.
49. Lee JS, Morrisett JD, Tung CH. Detection of hydroxyapatite in calcified cardiovascular tissues. Atherosclerosis 2012; 224: 340-47.
50. Kanzaki N, Treboux G, Onuma K et al. Calcium phosphate clusters. Biomaterials 2001; 22: 2921-9.
51. Kay MI, Young RA, Posner AS. Crystal Structure of Hydroxyapatite. Nature 1964; 204: 1050-52.
52. Posner AS, Betts F. Synthetic amorphous calcium phosphate and its relation to bone mineral structure. Acc. Chem. Res. 1975; 8: 273-81.
53. Nancollas GH, Johnsson MA. Calculus formation and inhibition. Adv Dent Res 1994; 8: 307-11.
54. Tomazic BB, Brown WE, Schoen FJ. Physicochemical properties of calcific deposits isolated from porcine bioprosthetic heart valves removed from patients following 2-13 years function. J Biomed Mater Res 1994; 28: 35-47.
55. Price PA, Chan WS, Jolson DM, Williamson MK. The elastic lamellae of devitalized arteries calcify when incubated in serum: evidence for a serum calcification factor. Arterioscler Thromb Vasc Biol 2006; 26: 1079-85.
56. Khavandgar Z, Roman H, Li J et al. Elastin Haploinsufficiency Impedes the Progression of Arterial Calcification in MGPDeficient Mice. J Bone Miner Res 2014; 29: 327-37.
57. Hosaka N, Mizobuchi M, Ogata H et al. Elastin degradation accelerates phosphate-induced mineralization of vascular smooth muscle cells. Calcif Tissue Int 2009; 85: 523-9.
58. Alfrey AC, Ibels LS. Role of phosphate and pyrophosphate in soft tissue calcification. Adv Exp Med Biol 1978; 103: 187-93.
59. Fleisch H. Inhibitors and promoters of stone formation. Kidney Int 1978; 13: 361-71.
60. Schlieper G, Westenfeld R, Brandenburg V, Ketteler M. Inhibitors of calcification in blood and urine. Semin Dial 2007; 20: 113-21.
61. Lomashvili KA, Khawandi W, O'Neill WC. Reduced plasma pyrophosphate levels in hemodialysis patients. J Am Soc Nephrol 2005; 16: 2495-2500.
62. O'Neill WC, Sigrist MK, McIntyre CW. Plasma pyrophosphate and vascular calcification in chronic kidney disease. Nephrol Dial Transplant 2010; 25: 187-91.
63. Lomashvili KA, Cobbs S, Hennigar RA et al. Phosphate-induced vascular calcification: role of pyrophosphate and osteopontin. J Am Soc Nephrol 2004; 15: 1392-1401.
64. Villa-Bellosta R, Wang X, Millan JL et al. Extracellular pyrophosphate metabolism and calcification in vascular smooth muscle. Am J Physiol Heart Circ Physiol 2011; 301: H61-68.
65. Lomashvili KA, Garg P, Narisawa S et al. Upregulation of alkaline phosphatase and pyrophosphate hydrolysis: potential mechanism for uremic vascular calcification. Kidney Int 2008; 73: 1024-30.
66. Narisawa S, Yadav MC, Millan JL. In vivo overexpression of tissue-nonspecific alkaline phosphatase increases skeletal mineralization and affects the phosphorylation status of osteopontin. J Bone Miner Res 2013; 28: 1587-98.
67. Narisawa S, Harmey D, Yadav MC et al. Novel inhibitors of alkaline phosphatase suppress vascular smooth muscle cell calcification. J Bone Miner Res 2007; 22: 1700-1710.
68. Kiffer-Moreira T, Yadav MC, Zhu D et al. Pharmacological inhibition of PHOSPHO1 suppresses vascular smooth muscle cell calcification. J Bone Miner Res 2013; 28: 81-91.
69. Yadav MC, Simao AM, Narisawa S et al. Loss of skeletal mineralization by the simultaneous ablation of PHOSPHO1 and alkaline phosphatase function: a unified model of the mechanisms of initiation of skeletal calcification. J Bone Miner Res 2011; 26: 286-97.
70. Rutsch F, Ruf N, Vaingankar S et al. Mutations in ENPP1 are associated with 'idiopathic' infantile arterial calcification. Nat Genet 2003; 34: 379-81.
71. Ruf N, Uhlenberg B, Terkeltaub R et al. The mutational spectrum of ENPP1 as arising after the analysis of 23 unrelated patients with generalized arterial calcification of infancy (GACI). Hum Mutat 2005; 25: 98.
72. Koshizuka Y, Ikegawa S, Sano M et al. Isolation of novel mouse genes associated with ectopic ossification by differential display method using ttw, a mouse model for ectopic ossification. Cytogenet Cell Genet 2001; 94: 163-8.
73. Cecil DL, Terkeltaub RA. Arterial calcification is driven by RAGE in Enpp1-/- mice. J Vasc Res 2011; 48: 227-35.
74. Johnson K, Polewski M, van Etten D, Terkeltaub R. Chondrogenesis mediated by PPi depletion promotes spontaneous aortic calcification in NPP1-/- mice. Arterioscler Thromb Vasc Biol 2005; 25: 686-91.
75. St Hilaire C, Ziegler SG, Markello TC et al. NT5E mutations and arterial calcifications. N Engl J Med 2011; 364: 432-42.
76. Ciancaglini P, Yadav MC, Simao AM et al. Kinetic analysis of substrate utilization by native and TNAP-, NPP1-, or PHOSPHO1- deficient matrix vesicles. J Bone Miner Res 2010; 25: 716-23.
77. Pettengill M, Robson S, Tresenriter M et al. Soluble ecto-5'- nucleotidase (5'-NT), alkaline phosphatase, and adenosine deaminase (ADA1) activities in neonatal blood favor elevated extracellular adenosine. J Biol Chem 2013; 288: 27315-26.
78. Street SE, Kramer NJ, Walsh PL et al. Tissue-nonspecific alkaline phosphatase acts redundantly with PAP and NT5E to generate adenosine in the dorsal spinal cord. J Neurosci 2013; 33: 11314-22.
79. Abraham EH, Prat AG, Gerweck L et al. The multidrug resistance (mdr1) gene product functions as an ATP channel. Proc Natl Acad Sci U S A 1993; 90: 312-16.
80. Reisin IL, Prat AG, Abraham EH et al. The cystic fibrosis transmembrane conductance regulator is a dual ATP and chloride channel. J Biol Chem 1994; 269: 20584-91.
81. Schwiebert EM, Egan ME, Hwang TH et al. CFTR regulates outwardly rectifying chloride channels through an autocrine mechanism involving ATP. Cell 1995; 81: 1063-73.
82. Stout CE, Costantin JL, Naus CC, Charles AC. Intercellular calcium signaling in astrocytes via ATP release through connexin hemichannels. J Biol Chem 2002; 277: 10482-8.
83. Bao L, Locovei S, Dahl G. Pannexin membrane channels are mechanosensitive conduits for ATP. FEBS Lett 2004; 572: 65-68.
84. Feranchak AP, Lewis MA, Kresge C et al. Initiation of purinergic signaling by exocytosis of ATP-containing vesicles in liver epithelium. J Biol Chem 2010; 285: 8138-47.
85. Bergen AA, Plomp AS, Schuurman EJ et al. Mutations in ABCC6 cause pseudoxanthoma elasticum. Nat Genet 2000; 25: 228-31.
86. Le Saux O, Urban Z, Tschuch C et al. Mutations in a gene encoding an ABC transporter cause pseudoxanthoma elasticum. Nat Genet 2000; 25: 223-7.
87. Ho AM, Johnson MD, Kingsley DM. Role of the mouse ank gene in control of tissue calcification and arthritis. Science 2000; 289: 265-70.
88. Bercovitch RS, Januario JA, Terry SF et al. Testicular microlithiasis in association with pseudoxanthoma elasticum. Radiology 2005; 237: 550-54.
89. Kruh GD, Belinsky MG. The MRP family of drug efflux pumps. Oncogene 2003; 22: 7537-52.
90. Sodani K, Patel A, Kathawala RJ, Chen ZS. Multidrug resistance associated proteins in multidrug resistance. Chin J Cancer 2012; 31: 58-72.
91. Nurnberg P, Thiele H, Chandler D et al. Heterozygous mutations in ANKH, the human ortholog of the mouse progressive ankylosis gene, result in craniometaphyseal dysplasia. Nat Genet 2001; 28: 37-41.
92. Reichenberger E, Tiziani V, Watanabe S et al. Autosomal dominant craniometaphyseal dysplasia is caused by mutations in the transmembrane protein ANK. Am J Hum Genet 2001; 68: 1321-6.
93. Gurley KA, Reimer RJ, Kingsley DM. Biochemical and genetic analysis of ANK in arthritis and bone disease. Am J Hum Genet 2006; 79: 1017-29.
94. Costello JC, Rosenthal AK, Kurup IV et al. Parallel regulation of extracellular ATP and inorganic pyrophosphate: roles of growth factors, transduction modulators, and ANK. Connect Tissue Res 2011; 52: 139-46.
95. Pendleton A, Johnson MD, Hughes A et al. Mutations in ANKH cause chondrocalcinosis. Am J Hum Genet 2002; 71: 933-40.
96. Williams CJ, Zhang Y, Timms A et al. Autosomal dominant familial calcium pyrophosphate dihydrate deposition disease is caused by mutation in the transmembrane protein ANKH. Am J Hum Genet 2002; 71: 985-91.
97. Williams CJ, Pendleton A, Bonavita G et al. Mutations in the amino terminus of ANKH in two US families with calcium pyrophosphate dihydrate crystal deposition disease. Arthritis Rheum 2003; 48: 2627-31.
98. Wang W, Xu J, Du B, Kirsch T. Role of the progressive ankylosis gene (ank) in cartilage mineralization. Mol Cell Biol 2005; 25: 312-323.
99. Foster BL, Nociti FH, Jr., Swanson EC et al. Regulation of cementoblast gene expression by inorganic phosphate in vitro. Calcif Tissue Int 2006; 78: 103-12.
100. Addison WN, Azari F, Sorensen ES et al. Pyrophosphate inhibits mineralization of osteoblast cultures by binding to mineral, upregulating osteopontin, and inhibiting alkaline phosphatase activity. J Biol Chem 2007; 282: 15872-83.
101. Zhang Y, Brown MA, Peach C et al. Investigation of the role of ENPP1 and TNAP genes in chondrocalcinosis. Rheumatology (Oxford) 2007; 46: 586-9.
102. Wang J, Tsui HW, Beier F et al. The ANKH DeltaE490Mutation in Calcium Pyrophosphate Dihydrate Crystal Deposition Disease (CPPDD) affects tissue non-specific Alkaline Phosphatase (TNAP) activities. Open Rheumatol J 2008; 2: 23-30.
103. Wang J, Tsui HW, Beier F, Tsui FW. The CPPDD-associated ANKH M48T mutation interrupts the interaction of ANKH with the sodium/phosphate cotransporter PiT-1. J Rheumatol 2009; 36: 1265-72.
104. Couto AR, Zhang Y, Timms A et al. Investigating ANKH and ENPP1 in Slovakian families with chondrocalcinosis. Rheumatol Int 2012; 32: 2745-51.
105. Zimmermann H, Zebisch M, Strater N. Cellular function and molecular structure of ecto-nucleotidases. Purinergic Signal 2012; 8: 437-502.
106. Biber J, Hernando N, Forster I. Phosphate transporters and their function. Annu Rev Physiol 2013; 75: 535-50.
107. Forster IC, Hernando N, Biber J, Murer H. Phosphate transporters of the SLC20 and SLC34 families. Mol Aspects Med 2013; 34: 386-95.
108. Villa-Bellosta R, Sorribas V. Role of rat sodium/phosphate cotransporters in the cell membrane transport of arsenate. Toxicol Appl Pharmacol 2008; 232: 125-34.
109. Villa-Bellosta R, Sorribas V. Compensatory regulation of the sodium/phosphate cotransporters NaPi-IIc (SCL34A3) and Pit-2 (SLC20A2) during Pi deprivation and acidosis. Pflugers Arch 2010; 459: 499-508.
110. Forster IC, Hernando N, Biber J, Murer H. Phosphate transport kinetics and structure-function relationships of SLC34 and SLC20 proteins. Curr Top Membr 2012; 70: 313-56.
111. Wagner CA, Hernando N, Forster IC, Biber J. The SLC34 family of sodium-dependent phosphate transporters. Pflugers Arch 2014; 466: 139-53.
112. Silverstein DM, Barac-Nieto M, Murer H, Spitzer A. A putative growth-related renal Na(+)-Pi cotransporter. Am J Physiol 1997; 273: R928-33.
113. Segawa H, Kaneko I, Takahashi A et al. Growth-related renal type II Na/Pi cotransporter. J Biol Chem 2002; 277: 19665-72.
114. Beck L, Karaplis AC, Amizuka N et al. Targeted inactivation of Npt2 in mice leads to severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities. Proc Natl Acad Sci U S A 1998; 95: 5372-7.
115. Ichikawa S, Sorenson AH, Imel EA et al. Intronic deletions in the SLC34A3 gene cause hereditary hypophosphatemic rickets with hypercalciuria. J Clin Endocrinol Metab 2006; 91: 4022-7.
116. Bergwitz C, Roslin NM, Tieder M et al. SLC34A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria predict a key role for the sodium-phosphate cotransporter NaPi-IIc in maintaining phosphate homeostasis. Am J Hum Genet 2006; 78: 179-92.
117. Lorenz-Depiereux B, Benet-Pages A, Eckstein G et al. Hereditary hypophosphatemic rickets with hypercalciuria is caused by mutations in the sodium-phosphate cotransporter gene SLC34A3. Am J Hum Genet 2006; 78: 193-201.
118. Sabbagh Y, O'Brien SP, Song W et al. Intestinal npt2b plays a major role in phosphate absorption and homeostasis. J Am Soc Nephrol 2009; 20: 2348-58.
119. Corut A, Senyigit A, Ugur SA et al. Mutations in SLC34A2 cause pulmonary alveolar microlithiasis and are possibly associated with testicular microlithiasis. Am J Hum Genet 2006; 79: 650-56.
120. Huqun, Izumi S, Miyazawa H et al. Mutations in the SLC34A2 gene are associated with pulmonary alveolar microlithiasis. Am J Respir Crit Care Med 2007; 175: 263-8.
121. Collins JF, Bai L, Ghishan FK. The SLC20 family of proteins: dual functions as sodium-phosphate cotransporters and viral receptors. Pflugers Arch 2004; 447: 647-52.
122. Bottger P, Hede SE, Grunnet M et al. Characterization of transport mechanisms and determinants critical for Na+-dependent Pi symport of the PiT family paralogs human PiT1 and PiT2. Am J Physiol Cell Physiol 2006; 291: C1377-87.
123. Yoshiko Y, Candeliere GA, Maeda N, Aubin JE. Osteoblast autonomous Pi regulation via Pit1 plays a role in bone mineralization. Mol Cell Biol 2007; 27: 4465-74.
124. Beck L, Leroy C, Salaun C et al. Identification of a novel function of PiT1 critical for cell proliferation and independent of its phosphate transport activity. J Biol Chem 2009; 284: 31363-74.
125. Salaun C, Leroy C, Rousseau A et al. Identification of a novel transport-independent function of PiT1/SLC20A1 in the regulation of TNF-induced apoptosis. J Biol Chem 2010; 285: 34408-18.
126. Cecil DL, Rose DM, Terkeltaub R, Liu-Bryan R. Role of interleukin-8 in PiT-1 expression and CXCR1-mediated inorganic phosphate uptake in chondrocytes. Arthritis Rheum 2005; 52: 144- 54.
127. Mansfield K, Teixeira CC, Adams CS, Shapiro IM. Phosphate ions mediate chondrocyte apoptosis through a plasma membrane transporter mechanism. Bone 2001; 28: 1-8.
128. Beck L, Leroy C, Beck-Cormier S et al. The phosphate transporter PiT1 (Slc20a1) revealed as a new essential gene for mouse liver development. PLoS One 2010; 5: e9148.
129. Crouthamel MH, Lau WL, Leaf EM et al. Sodium-dependent phosphate cotransporters and phosphate-induced calcification of vascular smooth muscle cells: redundant roles for PiT-1 and PiT-2. Arterioscler Thromb Vasc Biol 2013; 33: 2625-32.
130. Jensen N, Schroder HD, Hejbol EK et al. Loss of function of Slc20a2 associated with familial idiopathic Basal Ganglia calcification in humans causes brain calcifications in mice. J Mol Neurosci 2013; 51: 994-9.